Physician profile
May Chan
NPI 1891179545
$4,942.59
in general payments reported to CMS, 2019-2025
21 companies · $1,478 in 2025
The $1,478 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $191 · 2021: $292 · 2022: $1,006 · 2023: $987 · 2024: $674 · 2025: $1,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,138.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $819.99 | 2022-2025 | Lumigan, Durysta, Xen Glaucoma Treatment System |
| Alcon Vision LLC | $548.37 | 2022-2025 | Rocklatan, Tryptyr, Eysuvis |
| Sun Pharmaceutical Industries INC. | $387.52 | 2021-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $373.88 | 2019-2023 | |
| Harrow Eye, LLC | $364.27 | 2024-2025 | Vevye, Iheezo |
| Bausch & Lomb Americas INC. | $345.01 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Mallinckrodt Hospital Products INC. | $300.00 | 2022-2025 | Acthar |
| Oyster Point Pharma, INC. | $288.89 | 2022-2025 | Tyrvaya |
| Allergan, INC. | $270.66 | 2019-2022 | |
| Thea Pharma INC. | $195.05 | 2023-2025 | Iyuzeh |
| Dompe US, INC. | $155.90 | 2022-2025 | Oxervate |
| Shire North American Group INC | $150.69 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $145.69 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $131.94 | 2019-2023 | Flarex |
| Rxsight INC | $124.03 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $86.49 | 2022-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $86.44 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $71.38 | 2020-2021 | |
| Amgen INC. | $51.67 | 2025 | Tepezza |
| Biotissue Holdings INC. | $28.79 | 2022-2023 | |
| Sight Sciences, INC. | $15.93 | 2023 | Tearcare System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw May Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.